Periodontal Therapeutics Market to Reach USD 1,950.35 Million by 2033 at 7.2% CAGR; North America Leads with 38% Share - Key Players: Pfizer Inc., Bausch Health, Sun Pharma

The global periodontal therapeutics market reached USD 1,005.93 million in 2024 and is expected to reach USD 1,950.35 million by 2033, growing at a CAGR of 7.2% during the forecast period from 2025 to 2033. The market is experiencing steady growth driven by the increasing prevalence of periodontal diseases and the growing awareness of oral health worldwide.

Market growth is primarily fueled by the rising incidence of gum-related disorders such as gingivitis and periodontitis, particularly among the aging population. Changing lifestyles, poor oral hygiene habits, and increasing consumption of tobacco and sugary foods are further contributing to the growing burden of periodontal diseases. Additionally, the rising demand for advanced and minimally invasive dental treatments, along with increasing dental care expenditure, is supporting market expansion.

Periodontal therapeutics play a critical role in preventing, managing, and treating gum diseases through a range of solutions including antibiotics, antiseptics, and regenerative therapies. These treatments help reduce inflammation, control infection, and promote tissue regeneration. Continuous advancements in drug delivery systems, laser therapies, and biologics are enhancing treatment outcomes and patient compliance. Furthermore, growing adoption of preventive dental care and increasing access to dental services, especially in emerging economies, are positioning the periodontal therapeutics market as an important segment within the global oral healthcare industry.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/periodontal-therapeutics-market?sai-v

Key Developments

✅ February 2026: Across North America, Europe, and Asia Pacific, rising prevalence of gum diseases such as gingivitis and periodontitis significantly accelerated demand for periodontal therapeutics, with over a billion global cases driving long-term treatment needs.

✅ January 2026: Globally, advancements in targeted antimicrobial therapies, anti-inflammatory drugs, and site-specific drug delivery systems improved treatment outcomes by reducing infection, controlling inflammation, and slowing disease progression.

✅ December 2025: Leading companies such as Pfizer Inc., Teva Pharmaceuticals USA, Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Cipla, Inc. expanded portfolios in antibiotic therapies (doxycycline, minocycline), oral care products, and adjunctive periodontal treatments, strengthening global market presence.

✅ November 2025: Increasing adoption of combination therapies, scaling and root planing (SRP) adjuncts, and antimicrobial mouth rinses improved clinical outcomes and enhanced patient compliance in managing moderate-to-severe periodontal disease.

✅ October 2025: Companies intensified investments in biologic therapies, nanotechnology-based drug delivery, and regenerative approaches aimed at restoring gum tissue and improving long-term oral health outcomes.

✅ September 2025: Across key regions including the United States, Europe, China, Japan, and India, increasing oral health awareness, rising geriatric population, and integration of dental care into primary healthcare systems significantly supported market growth.

The market is rapidly evolving toward preventive and regenerative periodontal care, where advanced drug delivery, biologics, and personalized dental therapies are transforming traditional gum disease management into a more effective and patient-centric approach.

Key Players
Pfizer Inc. | Lupin Limited | Teva Pharmaceutical Industries Ltd. | Sun Pharmaceutical Industries Limited | Cipla | Advacare | Bausch Health Companies Inc. | US Antibiotics | Melinta Therapeutics | Others
Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=periodontal-therapeutics-market?sai-v

Market Drivers

Rising prevalence of periodontal diseases such as gingivitis and periodontitis is significantly driving demand for periodontal therapeutics.

Increasing aging population is more susceptible to oral health issues, contributing to higher treatment demand.

Growing awareness regarding oral hygiene and preventive dental care is boosting early diagnosis and treatment adoption.

Rising incidence of lifestyle-related risk factors such as smoking, diabetes, and poor oral hygiene is accelerating disease burden.

Increasing demand for minimally invasive and non-surgical periodontal treatments is supporting market growth.

Advancements in dental care technologies and therapeutics, including antimicrobial agents and regenerative materials, are improving treatment outcomes.

Expanding dental care infrastructure and rising healthcare expenditure are further driving market expansion.

Industry Developments

Rapid advancement in localized drug delivery systems such as antimicrobial gels, fibers, and chips for targeted periodontal treatment.

Increasing adoption of regenerative therapies including bone grafts, guided tissue regeneration (GTR), and growth factors.

Growing use of laser-assisted periodontal therapy for improved precision and reduced patient discomfort.

Expansion of biologics and host modulation therapies to enhance tissue regeneration and healing.

Rising integration of digital dentistry and imaging technologies for accurate diagnosis and treatment planning.

Strategic collaborations among dental product manufacturers and research institutions to develop innovative solutions.

Continuous innovation in combination therapies integrating mechanical and pharmacological treatments.

Regional Insights

North America 38% share: "Leads the market due to high awareness of oral health, advanced dental care infrastructure, and strong adoption of innovative periodontal treatments."

Europe 27% share: "Growth driven by increasing prevalence of periodontal diseases and strong healthcare systems."

Asia Pacific 23% share: "Fastest-growing region supported by large patient population, rising awareness, and improving dental care infrastructure."

Latin America 6% share: "Emerging growth driven by increasing access to dental services and rising awareness of oral hygiene."

Middle East & Africa 6% share: "Steady growth supported by improving healthcare facilities and gradual adoption of advanced dental treatments."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/periodontal-therapeutics-market?sai-v

Key Segments

➥ By Disease Type
Chronic Periodontitis: Represents the dominant segment, driven by its high prevalence among adults and the need for long-term management and treatment.

Gingivitis: Represents a significant segment, characterized by early-stage gum inflammation and increasing awareness leading to early diagnosis and treatment.

Aggressive Periodontitis: Represents a notable segment, involving rapid progression and requiring intensive therapeutic intervention.

Others: Include necrotizing periodontal diseases and other less common conditions requiring specialized care.

➥ By Drug Type
Chlorhexidine: Represents the dominant segment, widely used as an antiseptic mouthwash for controlling plaque and preventing infection.

Doxycycline: Represents a significant segment, used for its antibacterial and anti-inflammatory properties in periodontal therapy.

Metronidazole: Represents a notable segment, effective against anaerobic bacteria associated with periodontal infections.

Minocycline: Represents a growing segment, often used in localized drug delivery systems for targeted treatment.

Rapamycin: Represents an emerging segment, supported by research into its anti-inflammatory and regenerative properties.

Others: Include combination therapies and newer antimicrobial agents.

➥ By Route of Administration
Oral: Represents the dominant segment, driven by ease of administration and widespread use of antibiotics and antiseptic formulations.

Parenteral: Represents a limited but important segment, primarily used in severe infections or advanced cases requiring systemic intervention.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.